📣 Media Alert! Check out CEO Alif Saleh's interview in PharmaVoice discussing neuro drug development and AxoSim.
While enthusiasm is high in the push to develop new drugs for neurological disorders like epilepsy, #Alzheimer’s and #Parkinson’s disease, the vast majority of investigational medications still don’t make it far — and 92% fail when they reach human testing. “Neuro has one of the highest failure rates and one of the highest investment rates and that means something is wrong,” said Alif Saleh, CEO of AxoSim, a Louisiana-based biotech with a brain-on-a-chip platform. https://lnkd.in/e_8NeaRp